TY - JOUR
T1 - Irinotecan plus mitomycin c as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and cisplatin
T2 - A retrospective study
AU - Ogawa, Kohei
AU - Hosokawa, Ayumu
AU - Ueda, Akira
AU - Saito, Seiko
AU - Mihara, Hiroshi
AU - Ando, Takayuki
AU - Kajiura, Shinya
AU - Terada, Mitsuhiro
AU - Tsukioka, Yuji
AU - Horikawa, Naoki
AU - Kobayashi, Takashi
AU - Note, Masayuki
AU - Sawasaki, Kunihiro
AU - Fukuoka, Junya
AU - Sugiyama, Toshiro
PY - 2012
Y1 - 2012
N2 - Background. S-1 plus cisplatin has been established to be standard first-line chemotherapy for advanced gastric cancer in Japan. The optimal second-line treatment refractory to S-1 plus cisplatin remains unclear. Methods. We retrospectively studied the efficacy, toxicity, and survival of irinotecan plus mitomycin C in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin. Results. Twenty-four patients were studied. Prior chemotherapy was S-1 plus cisplatin in 15 patients, S-1 plus cisplatin and docetaxel in 8, and 5-fluorouracil plus cisplatin with radiotherapy in 1. The overall response rate was 17.4%. The median overall survival was 8.6 months, and the median progression-free survival was 3.6 months. Grade 3 or 4 toxicities included leukopenia (33%), neutropenia (50%), anemia (33%), thrombocytopenia (4%), anorexia (13%), diarrhea (4%), and febrile neutropenia (13%). Conclusion. A combination of irinotecan and mitomycin C is potentially effective in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin.
AB - Background. S-1 plus cisplatin has been established to be standard first-line chemotherapy for advanced gastric cancer in Japan. The optimal second-line treatment refractory to S-1 plus cisplatin remains unclear. Methods. We retrospectively studied the efficacy, toxicity, and survival of irinotecan plus mitomycin C in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin. Results. Twenty-four patients were studied. Prior chemotherapy was S-1 plus cisplatin in 15 patients, S-1 plus cisplatin and docetaxel in 8, and 5-fluorouracil plus cisplatin with radiotherapy in 1. The overall response rate was 17.4%. The median overall survival was 8.6 months, and the median progression-free survival was 3.6 months. Grade 3 or 4 toxicities included leukopenia (33%), neutropenia (50%), anemia (33%), thrombocytopenia (4%), anorexia (13%), diarrhea (4%), and febrile neutropenia (13%). Conclusion. A combination of irinotecan and mitomycin C is potentially effective in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin.
UR - http://www.scopus.com/inward/record.url?scp=84863379547&partnerID=8YFLogxK
U2 - 10.1155/2012/640401
DO - 10.1155/2012/640401
M3 - 学術論文
C2 - 22474446
AN - SCOPUS:84863379547
SN - 1687-6121
JO - Gastroenterology Research and Practice
JF - Gastroenterology Research and Practice
M1 - 640401
ER -